SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and ...
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...
Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback